Freedom Broker upgrades Biogen stock rating on Apellis acquisition

Biogen reported Q1 2026 non-GAAP EPS of $3.57, up 18% year over year, on revenue of about $2.48B, which beat consensus by 10%. Freedom Broker upgraded the stock to Buy and lifted its price target to $245 from $185, citing strong growth-product performance and the strategic Apellis acquisition, while also raising its valuation multiples. The company trimmed EPS guidance because of one-time charges, but analysts still forecast fiscal 2026 EPS of $14.64.

Analysis

The market is starting to re-rate BIIB less as a melting-ice-cube royalty stream and more as a self-funded pipeline/portfolio transition story. The important second-order effect is that the new capital allocation signal can compress the company’s perceived execution risk premium: if management can use M&A to offset patent/decline pressure while preserving buybacks, the equity deserves a higher multiple even before the acquired asset contributes meaningfully. That said, the current move is likely front-loading a lot of the thesis before the transaction is fully digested in model revisions.

The key watch item is not near-term EPS but the durability of the growth-products mix. Once the legacy franchise share shifts below a certain threshold, incremental revenue quality improves materially because the market stops underwritting the stock on a single-product decay curve; that can drive multiple expansion faster than consensus EPS upgrades. The flip side is that if the acquisition introduces integration drag, the stock could mean-revert quickly because the current valuation still leaves limited room if the market reclassifies the deal as defensive rather than accretive.

Consensus appears to be missing that BIIB can work as a sentiment trade on de-risking in biotech: a clean quarter plus a credible M&A offset can pull in generalist capital even if long-only healthcare managers remain cautious on ultimate growth durability. The overhang is that analyst estimate cuts and the still-elevated earnings multiple create a narrow runway for disappointment. In other words, the stock can grind higher on story improvement, but the path is vulnerable to any signal that the upcoming readouts or integration timeline slip.

The better setup may be to own the stock into the next catalyst window rather than chase the immediate pop, because the stock is likely to trade on revisions rather than headlines from here. If the next quarter confirms the mix shift and management gives explicit post-deal financial framing, the multiple can still re-rate another turn or two. If not, the name becomes a crowded long with little downside protection.

Key Decisions for Investors

• Long BIIB on pullbacks over the next 2-6 weeks; target a move toward the low-$200s if management sustains execution and post-deal confidence improves. Risk/reward is better on retracement than after a vertical move because the stock is already discounting a meaningful portion of the good news.
• Buy BIIB Jan-2027 call spreads to express a multi-quarter re-rating thesis while limiting downside to premium; structure for upside if the company proves the new portfolio mix is durable and integration is smooth.
• Pair trade: long BIIB / short a basket of slower-growth large-cap biotech names with less visible revenue replacement, over the next 3-9 months. The relative-value case is that BIIB has a clearer path to de-risking the top line than peers still depending on mature franchises.
• If BIIB fails to hold post-news support after the next earnings/update cycle, fade the move with a tactical short or put spread for a 1-2 month mean reversion trade. The setup breaks if the market decides the acquisition is merely defensive and estimate cuts continue.